H3B-6545 is an orally bioavailable, selective estrogen receptor covalent antagonist (SERCA) for research. It is utilized in studies of ERalpha-positive, HER2-negative metastatic breast cancer, demonstrating activity in both in vitro cellular assays and in vivo xenograft models.